First Patient Treated with Federally Approved Lyfgenia™ for the Curative Gene Therapy Treatment of Sickle Cell Disease Leaves Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center

First Patient Treated with Federally Approved Lyfgenia™ for the Curative Gene Therapy Treatment of Sickle Cell Disease Leaves Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center

The completion of the patient’s treatment for sickle cell is the second pediatric curative gene therapy treatment completed this year on the Hackensack University Medical Center campus. The Lyfgenia treatment comes on the heels of Joseph M. Sanzari’s treatment of a young girl who underwent treatment for another inherited blood disorder. The patient was treated with beta thalassemia using Zynteglo, which was approved by the FDA for the treatment o